A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) In Combination with Axitinib (INLYTA®) Versus Sunitinib (SUTENT®) Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma